An observational study in Atherosclerotic Cardiovascular Disease, sponsored by Sanofi. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Sanofi · Observational
This study will evaluate cardiovascular outcomes among individuals with clinically established atherosclerotic cardiovascular disease (ASCVD) who have not previously experienced a myocardial infarction (MI) or ischemic stroke. The study will evaluate a composite outcome comprising nonfatal MI, nonfatal ischemic stroke, cardiovascular death, and/or all-cause mortality. Additionally, risk factors for experiencing cardiovascular outcomes and lipid lowering therapy use will be evaluated.
1,517 studies on the registry are indexed under Atherosclerosis; 224 are open to participants now.
This study's enrollment of 180,000 is above the median of 250 across 527 observational studies indexed under Atherosclerosis.
Browse Atherosclerosis studies →Sanofi is the lead sponsor of 1,557 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants with evidence of ASCVD will be identified using diagnostic and procedural codes during a predefined identification period, January 1, 2016, to December 31, 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Prior history of ASCVD before the index date, including myocardial infarction, ischemic stroke, unstable angina, coronary revascularization, carotid artery disease, peripheral artery disease, or other ASCVD diagnoses.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Participants with ASCVD and no prior history of ischemic events, including myocardial infarction or ischemic stroke, at cohort entry.
Major Adverse Cardiovascular Events
Composite of nonfatal myocardial infarction, nonfatal ischemic stroke, or all-cause mortality.
Time frame: From index up to 5 years follow up
Composite of Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or Cardiovascular Mortality
Time frame: From index date up to 5 years of follow-up
Occurrence of Nonfatal Myocardial Infarction
Time frame: From index date up to 5 years of follow-up
Occurrence of Nonfatal Ischemic Stroke
Time frame: From index date up to 5 years of follow-up
All-Cause Mortality
Death due to any cause during follow-up.
Time frame: From index date up to 5 years of follow-up
Cardiovascular Mortality
Cardiovascular death during follow-up.
Time frame: From index date up to 5 years of follow-up
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Jun 2026, 7 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.